Vivani Medical (VANI) investor relations material

Market landscape and unmet needs

• GLP-1 therapies have transformed obesity and type 2 diabetes care, with a crowded field of late-stage competitors focused on orals and longer-acting injectables.

• Poor adherence and persistence with current therapies limit real-world outcomes, with over 50% of patients not following prescribed regimens.

• Long-term health benefits of GLP-1s require sustained treatment, but only 40% of patients remain on semaglutide after one year.

• There is significant interest in long-acting solutions, as shown by patient and prescriber surveys and analogies to the contraception market.

Technology and product development

• The NanoPortal platform enables subdermal implants for infrequent dosing, with precise drug release via titanium oxide nanotubes.

• Lead program NPM-139 is a six-month semaglutide implant for obesity, with plans to expand to type 2 diabetes and other molecules.

• Preclinical studies showed sustained weight loss and liver fat reduction, with favorable safety and tolerability in human trials using exenatide.

• The implant is inserted via a simple in-office procedure, similar to NEXPLANON, and is biocompatible and biostable.

Clinical progress and partnerships

• The SLIM-1 phase I trial for the semaglutide implant rapidly enrolled and is ongoing, with top-line data expected in November.

• A technology evaluation agreement with Novo Nordisk is in place, and a dose-ranging phase II study is planned for next year.

• The implant demonstrated smooth, sustained pharmacokinetics and durable weight effects in preclinical and early clinical studies.

• The technology has also been tested with retatrutide, showing adaptability to new molecules.